Active Biotech AB

251 articles about Active Biotech AB

• Active Biotech AB and Ipsen Report for the First Time Tasquinimod (TASQ) Phase II Long Term Safety Data at the 27th European Association of Urology (EAU) Congress

  2/24/2012

• Active Biotech AB: Year-end Report January - December 2011

  2/16/2012

• Active Biotech AB's Prostate Cancer Project TASQ in Phase I Combination Therapy Trial

  1/23/2012

• Active Biotech AB to Present at the JP Morgan 30th Annual Healthcare Conference

  1/4/2012

• Active Biotech AB's Election Committee Appointed

  11/10/2011

• Active Biotech AB Interim Report January - September 2011

  11/3/2011

• Information Regarding Active Biotech AB's Candidate Drug Laquinimod

  11/2/2011

• Teva Pharmaceutical Industries Limited and Active Biotech AB Laquinimod Trial for MS Treatment Yields Positive Results

  10/20/2011

• Active Biotech AB's Prostate Cancer Project TASQ Featured in Journal of Clinical Oncology

  9/20/2011

• Active Biotech AB Interim Report January - June 2011

  8/11/2011

• Number of Shares and Votes in Active Biotech AB

  6/30/2011

• Active Biotech AB to Present at the Jefferies and Co. 2011 Global Healthcare Conference

  6/8/2011

• Evotec AG and Active Biotech AB Enter Into Medicinal Chemistry Collaboration

  6/6/2011

• Number of Shares and Votes in Active Biotech AB

  5/31/2011

• Active Biotech AB Presents Data Regarding the 57-57 Project at EULAR

  5/27/2011

• Annual General Meeting of Active Biotech AB

  5/6/2011

• Number of Shares and Votes in Active Biotech AB

  4/29/2011

• Active Biotech AB Interim Report January - March 2011

  4/28/2011

• Active Biotech AB's Partner Teva Pharmaceutical Industries Limited Comments on DEFINE Study Results in Multiple Sclerosis

  4/26/2011

• Active Biotech AB Receives Eur 25 Million Upfront from Ipsen as Part of Broad Tasquinimod Deal

  4/18/2011